Table 1. Patient characteristics.
| N = 34 | |
|---|---|
| Age (years) | |
| Median (range) | 54 (35-77) |
| Hormone receptors (HR) status | |
| Positive | 19 (55%) |
| Negative | 15 (45%) |
| HER2 status | |
| Positive | 7 (20%) |
| Negative | 27 (80%) |
| Tumor subtypes | |
| Triple-negative | 13 (38%) |
| HER2 | 7 (20%) |
| Luminal/HER2-negative | 14 (42%) |
| Metastases | |
| Synchronous | 8 (24%) |
| Metachronous | 26 (76%) |
| Disease-free interval (months) | |
| Median (range) | 49 (13-306) |
| < 24 months | 9 (35%) |
| ≥ 24 months | 17 (65%) |
| Previous treatment | |
| Cytotoxics (n, %) | 33 (97%) |
| Median number of lines (range) | 3 (1-9) |
| Nature (n, % of treated) | |
| Anthracylines | 30 (90%) |
| Taxanes | 32 (97%) |
| 5FU | 30 (90%) |
| Eribuline | 13 (39%) |
| Alkylating | 30 (90%) |
| Endocrine therapy (n, %) | 22 (35%) |
| Median number of lines (range) | 2 (1-5) |
| Nature (n, % of treated) | |
| Tamoxifen | 13 (59%) |
| Aromatase inhibitors | 22 (100%) |
| Fulvestrant | 3 (13%) |
| Everolimus-based | 6 (27%) |
| Anti-HER2 (n, %) | 7 (21%) |
| Median number of lines (range) | 4 (1-6) |
| Nature (n, % of treated) | |
| Trastuzumab | 7 (100%) |
| Lapatinib | 3 (43%) |
| Trastuzumab emtansine | 2 (29%) |